ABSTRACT
Mucopolysaccharidosis type I (MPS I) is caused by a deficiency of α-L-iduronidase (IDUA), resulting in accumulation of glycosaminoglycans (GAG) in lysosomes. Microencapsulation of recombinant cells is a promising gene/cell therapy approach that could overcome the limitations of the current available treatments. In the present study we produced alginate-poly-L-lysine-alginate (APA) microcapsules containing recombinant cells overexpressing IDUA, which were implanted in the subcutaneous space of MPS I mice in order to evaluate their potential effect as a treatment for this disease. APA microcapsules enclosing genetically modified Baby Hamster Kidney cells overexpressing IDUA were produced and implanted in the subcutaneous space of 4-month-old MPS I mice (Idua -/-). Treatment was performed using two cell concentrations: 8.3 × 107 and 8.3 × 106 cells/mL. Untreated MPS I and normal mice were used as controls. Microcapsules were retrieved and analyzed after treatment. Increased IDUA in the liver, kidney and heart was detected 24 h postimplantation. After 120 days, higher IDUA activity was detected in the liver, kidney and heart, in both groups, whereas GAG accumulation was reduced only in the high cell concentration group. Microcapsules analysis showed blood vessels around them, as well as inflammatory cells and a fibrotic layer. Microencapsulated cells were able to ameliorate some aspects of the disease, indicating their potential as a treatment. To achieve better performance of the microcapsules, improvements such as the modulation of inflammatory response are suggested.
Subject(s)
Drug Compounding , Iduronidase/chemistry , Injections, Subcutaneous , Mucopolysaccharidosis I/drug therapy , Alginates/chemistry , Animals , Capsules/chemistry , Cell Line , Cricetinae , Glycosaminoglycans/chemistry , Immune System , Inflammation , Kidney/drug effects , Lysosomes/chemistry , Mice , Mice, Inbred C57BL , Mice, Transgenic , Polylysine/analogs & derivatives , Polylysine/chemistry , Recombinant Proteins/chemistry , Tissue DistributionABSTRACT
The neonatal diarrhea in swine caused by enterotoxigenic Escherichia coli (ETEC) is responsible for high mortality and low growth rate in pigs and it is mainly dependent on the capacity of E. coli to attach to the surface of the small intestine, a property mediated by fimbria. In this study the faeC gene, which codes for the minor fimbrial subunit of E. coli K88ab, was cloned in the eukaryotic expression vector pcDNA3, associated or not to the Kozak sequence. Plasmid DNA of the two versions of the vaccine candidate was inoculated in mice by the intramuscular route, in two doses, at 0 and 21 days. The animals that received the DNA vaccine containing faeC associated to the Kozak sequence presented seroconversion significantly higher (P 0.05) than the one vaccinated with pcDNA3/faeC without the Kozak sequence.
A diarréia neonatal em suínos causada por Escherichia coli produtora de enterotoxinas (ETEC) é responsável por alta mortalidade e baixa taxa de crescimento de leitões. A habilidade de tais cepas causar doença é dependente principalmente da capacidade de E. coli aderir-se a mucosa do intestino delgado, que é mediada por fímbrias. Neste estudo o gene faeC, que codifica a subunidade menor da fímbria de E. coli K88ab, foi clonado no vetor de expressão em eucariotos pcDNA3, associado ou não à seqüência de KozaK. DNA plasmidial das duas versões da vacina foi inoculado em camundongos via intra-muscular, em duas doses, nos dias 0 e 21. Os animais que receberam a vacina de DNA contendo o faeC associado a seqüência de Kozak apresentaram soroconversões significativamente maiores (p 0,05) que os vacinados com pcDNA3/faeC sem a seqüência de Kozak.
